drugset / Trial / NCT04624984
PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
NaSingle-groupOpen-labelTreatment
Summary
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2025-04
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 50 mg/m2 | Oral |